Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic Gram-negative pathogen. In this study, we uti...
| Published in: | Heliyon |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844025020675 |